✉news WorldUS Politics first seen 3 h ago, last 1 h ago, peak #27
Five-Year Data on Duchenne Drug Brogidirsen Presented at Muscle Congress
Original: Brogidirsen (NS-089/NCNP-02) 5-Year Clinical Trial Data for the Treatment of Duchenne Muscular Dystrophy Presented at 2026 World Muscle Society Congress
Five-year clinical trial data for brogidirsen (NS-089/NCNP-02), an investigational treatment for Duchenne muscular dystrophy, has been presented at the 2026 World Muscle Society Congress. The long-term results are being shared with specialists in neuromuscular medicine, offering the fullest picture yet of the drug's safety and effectiveness over five years in patients with the muscle-wasting disease.
Why now: Long-term trial results for a potential Duchenne muscular dystrophy therapy are of keen interest to patients, families and clinicians awaiting new treatment options.
BrogidirsenDuchenne muscular dystrophyWorld Muscle Society
Rank over time, top of the chart is #1. 3 snapshots from 3 h ago to 1 h ago.
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/604034